Lirim Shemshedini

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 6

Top Topics

Reactive Oxygen Species

Antiretroviral Therapy

Top Venues

Endocrine oncology (Bristol, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Prabesh Khatiwada, Ujjwal Rimal, Zhengyang Han, Lirim Shemshedini
MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer. Endocrine oncology (Bristol, England) 4 (1) (2024)
Prabesh Khatiwada, Ujjwal Rimal, Zhengyang Han, Lirim Shemshedini
MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer. Endocrine oncology (Bristol, England) 4 (1) (2024)
Prabesh Khatiwada, Ujjwal Rimal, Mamata Malla, Zhengyang Han, Lirim Shemshedini
Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation. Endocrine oncology (Bristol, England) 3 (1) (2023)
Prabesh Khatiwada, Ujjwal Rimal, Zhengyang Han, Mamata Malla, Jun Zhou, Lirim Shemshedini
The Transmembrane Protein TM4SF3 Interacts with AR and AR-V7 and is Recruited to AR Target Genes. Endocrinology (2023)
Zhengyang Han, Ujjwal Rimal, Prabesh Khatiwada, Jacob Brandman, Jun Zhou, Muhammad Hussain, Ronald E Viola, Lirim Shemshedini
Dual-Acting Peptides Target EZH2 and AR: A New Paradigm for Effective Treatment of Castration-Resistant Prostate Cancer. Endocrinology 164 (1) (2022)
Jun Zhou, Shuai Gao, Chen-Lin Hsieh, Mamata Malla, Lirim Shemshedini
Peptide B targets soluble guanylyl cyclase α1 and kills prostate cancer cells. PloS one 12 (8) (2017)